靶向PHGDH上调降低谷胱甘肽水平并使耐药NRAS突变黑色素瘤对MEK抑制重新敏感
本研究在体内建立对MEK抑制剂PD0325901耐药的NRAS突变黑色素瘤人源异种移植瘤模型,发现耐药细胞对结构不同的MEKi trametinib交叉耐药,ERK1/2磷酸化及下游信号升高,同时丝氨酸合成通路及关键酶PHGDH上调。抑制PHGDH联合MEKi可降低耐药细胞的氧化应激耐受和增殖,提示靶向PHGDH可能克服MEKi耐药。
要点
- NRAS突变黑色素瘤MEKi耐药模型中PHGDH及丝氨酸合成通路上调。
- 耐药细胞对trametinib交叉耐药且ERK1/2磷酸化升高。
- 抑制PHGDH联合MEKi降低耐药细胞氧化应激耐受与增殖。
核心结论
- 靶向PHGDH是克服NRAS突变黑色素瘤MEK抑制剂耐药的潜在策略。
研究设计与样本
- 在体内生成对MEK抑制剂PD0325901耐药的人NRAS突变黑色素瘤异种移植瘤模型。
主要发现
- MEKi耐药细胞对结构不同的MEKi trametinib交叉耐药。
- MEKi耐药细胞ERK1/2磷酸化及下游信号升高。
- MEKi耐药细胞丝氨酸合成通路及PHGDH表达上调。
- 抑制PHGDH联合MEKi降低耐药细胞氧化应激耐受和增殖。
临床怎么用
- 对NRAS突变黑色素瘤MEKi耐药者,可考虑检测PHGDH/丝氨酸合成通路并探索联合PHGDH抑制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Melanomas frequently harbor activating NRAS mutations leading to activation of MAPK kinase (MEK) and extracellular signal-regulated kinase 1/2 signaling; however, the clinical efficacy of inhibitors to this pathway is limited by resistance. Tumors rewire metabolic pathways in response to stress signals such as targeted inhibitors and drug resistance, but most therapy-resistant preclinical models are generated in conditions that lack physiological metabolism. We generated human NRAS-mutant melanoma xenografts that were resistant to the MEK inhibitor (MEKi) PD0325901 in vivo. MEKi-resistant cells showed cross-resistance to the structurally distinct MEKi trametinib and elevated extracellular signal-regulated kinase 1/2 phosphorylation and downstream signaling. Additionally, we observed upregulation of the serine synthesis pathway and PHGDH, a key enzyme in this pathway. Suppressing PHGDH in MEKi-resistant cells together with MEKi treatment decreased oxidative stress tolerance and cell proliferation. Together, our data suggest targeting PHGDH as a potential strategy in overcoming MEKi resistance.
引用
- Nguyen MQ, Teh JLF, Purwin TJ, et al. Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase Inhibition. J Invest Dermatol. 2020. PMID: 32389536. doi:10.1016/j.jid.2020.02.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。